CTN Bulletin logo
October 14, 2021

Updates from NIDA

NIDA Renames AIDS Research Program to HIV Research Program

NIDA logoNIDA is pleased to announce that they are renaming the AIDS Research Program (ARP) to the NIDA HIV Research Program (HRP) to better characterize our scientific investment at the intersection of HIV and substance use disorders. The name change aligns their HIV related science with less stigmatizing language, and reflects more contemporary HIV research and management approaches and priorities.

When the ARP program began in 2004, science had only just begun developing improved antiretroviral medications that have transformed HIV from a fatal disease into a manageable and livable condition. NIDA’s HIV research portfolio continues to be the second largest at NIH (after the National Institute of Allergy and Infectious Diseases), and is committed to reducing the stigma that reduces access to care, and can harm mental health. While the name has changed, the mission continues. You can read more about this name change in this blog post from NIDA Director Nora D. Volkow.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

$100,000 "Start a SUD Startup" Challenge Announced

NIDA has announced this year's $100,000 for Start a SUD Startup Challenge, intended to support research ideas in the area of substance use disorders (SUDs) that can serve as the foundation for the development of successful new startups.

The challenge enables winners to test the premise that their research idea can be fostered into a biotech startup, with a goal of eventually contributing to the pool of innovative small business companies that can successfully compete for NIDA’s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) funding.

The Challenge offers up to ten awards of $10,000 each and technical expertise and mentoring from NIDA biomedical entrepreneurship experts. The deadline for applications is November 16, 2021.

Find out more here!

CTN Trial Progress

GraphRandomizations for Active Studies as of the October 12 trial Progress Report.

CTN-0060-A-1 - Enrolled 686

CTN-0079-A-1 - Enrolled 40   

CTN-0080 - Enrolled 68

CTN-0097 - Enrolled 173

CTN-0098 - Enrolled 4

CTN-0099 - Enrolled 663

CTN-0099-A-1 - Enrolled 85

CTN-0100
Discontinuation - Enrolled 19
Retention - Enrolled 82

CTN-0101 - Enrolled 74

This project is supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute, but the information on this site has not been reviewed by NIDA and does not necessarily reflect the views of the Institute.


· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

New in the CTN Dissemination Library

Validation and Threshold Identification of a Prescription Drug Monitoring Program Clinical Opioid Risk Metric with the WHO Alcohol, Smoking, and Substance Involvement Screening Test. Cochran G, et al. Drug and Alcohol Dependence 2021;228:109067. CTN-0093 primary outcomes

Recruitment into a Clinical Trial of People Living with Uncontrolled HIV Infection Who Inject Drugs: A Site Case Report from the CTN 67 CHOICES Study. Tookes H, et al. Journal of Behavioral Health Services & Research 2021 (in press). CTN-0067

Reductions in Tobacco Use in Naltrexone, Relative to Buprenorphine-Maintained Individuals with Opioid Use Disorder: Secondary Analysis from the National Drug Abuse Treatment Clinical Trials Network. Montgomery L, et al. Journal of Substance Abuse Treatment 2021;130:108489. CTN-0051

Sex-Based Differences in Psychiatric Symptoms and Opioid Abstinence During Buprenorphine/Naloxone Treatment in Adolescents with Opioid Use Disorders. Hammond CJ, et al. Journal of Substance Abuse Treatment 2021 (in press). CTN-0010

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

News from the Nodes

Health Systems

Kelly Young-Wolff, PhD, MPH, Health Systems Node faculty, conducted an analysis of more than 100,000 pregnancies in Kaiser Permanente Northern California and found a 25% increase in the rate of cannabis use early in pregnancy after the pandemic began in spring 2020.

Dr. Young-Wolff’s analysis was reported in a research letter in the September 27 issue of JAMA. The study found that in the year before the pandemic, 6.75% of pregnant women were using cannabis in early pregnancy, and during the pandemic that rate rose to 8.14% of pregnant women.

For a full description of the study, read more here.

Ohio Valley

CTN-0125: Using Integrative Data Analysis to Examine the Impact of Psychosocial Treatments for Black Cocaine Users Enrolled in the NIDA Drug Abuse Treatment Clinical Trials Network (CTN)

This new study will evaluate the effectiveness of substance use disorder treatments for Black people who use cocaine and is a joint effort between the OVN, the WSN, and the NEC. Kathy Burlew (UC/OVN) and Lesia Ruglass (CCNY/WSN) are Co-LIs for this project.

CTN-0129: The Great Plains Initiative

This new project will work with American Indian populations in the Great Plains to determine community-defined needs for identifying and addressing SUD issues and assess the feasibility and acceptability of telemedicine for MOUD. Dr. Donald Warne (UND/OVN) is the LI for this project.

Western States

The Western States Node is hosting its next speaker in their Addiction Sciences webinar series:

Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
Presenter: Dr. Christopher Stauffer

October 18, 2021 | 11:00am - 12:00pm PST

Connect via Zoom here.

 

 

Pacific Northwest

Michael McDonell, PhD, of WSU and the CTN Pacific Northwest Node and Richard Rawson, PhD of UCLA are editing a special issue of the Journal of Substance Abuse Treatment focused on the changing epidemiology and treatment of stimulant use disorder.

The editors invite quality research manuscripts on topics related to stimulant use such as:

  • Behavioral and pharmacotherapy innovations
  • Implementation and dissemination science
  • Treatment in medical and specialty care settings
  • Assessment and treatment of co-occurring psychiatric symptoms (psychosis, depression, e.g.)
  • Withdrawal management
  • Overdose prevention and treatment
  • Epidemiological and treatment studies involving underserved populations

To facilitate manuscript development, authors should submit an abstract (maximum of one page) of the proposed paper to Michael McDonell. The deadline for abstract submission is January 1, 2022.

Find out more here.


Protocol Update: CTN-0100

100 participants have been randomized in CTN-0100! The team at the Mountain Manor site in Baltimore, led by site PI Marc Fishman, has randomized the 81st participant in the Retention Phase and the 100th participant overall.

The final Wave 1 site, Huntsman Mental Health Institute (Utah), has been endorsed and has started engaging study participants.

Wave 2 sites all have sIRB approval and continue to prepare for endorsement, with the first of those expected to start late October or early November. Wave 2 sites are: Aspire Health Partners (Florida), Dartmouth-Hitchcock ATP (New Hampshire), Operation PAR (Florida), University of Pittsburgh IM-REP and CPCDS clinics (Pennsylvania), Shoreline (South Carolina), Tarzana (California), CAST at UAMS (Arkansas) and ASAP at UNM (New Mexico).

For study information, please contact RDD at rdd@nyulangone.org.

 

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

Upcoming CTN-Related Webinars

Attitudes & Stigma Around Addiction
October 27, 2021 | 11am-12:30pm PT

In this webinar, John Kelly, PhD, ABPP will discuss the fundamental causes of stigma and discrimination in relation to substance use disorder, review some of the paradoxical findings from the latest stigma research, and suggest how stigma and discrimination might be more systematically addressed to enhance care and outcomes for people with substance use disorder. Sponsored by the Western States Node and the Northwest and Pacific Southwest ATTCs. 1.5 CME or CE credits available. Register for the webinar here.

Measuring and Improving the Quality of Opioid Prescribing to Children and Young Adults
November 19, 2021 | 11am-12pm ET

The CTN Youth SIG has invited Kao-Ping Chua, MA, PhD (U. Michigan Medical School) to speak about opioid prescribing patterns that are associated with adverse events (overdose, e.g.) in youth, the prevalence and safety of opioid prescribing to youth, and ongoing efforts to reduce excessive opioid prescribing after surgery in children and young adults. Connect to the webinar here.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

New from the ATTC Network

 

 

News from NIDA

     

Published by the CTN Dissemination Library of the Pacific Northwest Node
Addictions, Drug & Alcohol Institute, University of Washington

This project is supported by a grant from the National Institute on Drug Abuse to the University of Washington Addictions, Drug & Alcohol Institute, but the information on this site has not been reviewed by NIDA and does not necessarily reflect the views of the Institute.

Unsubscribe | Subscribe